FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidn...

AZ preps for US filing of kidney disease anaemia drug

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.

Vifor joins forces with Evotec on kidney disease joint ventu...

Astellas gets nod in Japan for roxadustat, ahead of GSK riva...

FDA fast-tracks AZ's Farxiga in potential new CKD indication

The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney